ABSTRACT
Introduction The NIA-AA research framework proposes a purely biological definition of Alzheimer’s Disease (AD). This implies AD can be diagnosed based on biomarker abnormalities. While this brings opportunities, it also raises challenges.
Methods We conducted a systematic review by searching PubMed for publications on conveying AD biomarker results to individuals without dementia. Content was analyzed inductively.
Results We included 25 publications. From these we extracted 26 considerations, which we grouped according to their primary relevance to a clinical, personal, or societal context. Clinical considerations include (lack of) validity, utility, and disclosure protocols. Personal considerations cover psychological and behavioral implications, as well as the right to (not) know. Societal considerations comprise the risk of misconception, stigmatization, and discrimination. Overall, views were heterogeneous and often contradictory.
Discussion Perceptions on a diagnosis of AD before dementia vary widely. Empirical research is required, taking perspectives of medical professionals and the general public into account.
Competing Interest Statement
JvdS wrote a book for a layman's audience about the personal impact of Dominantly Inherited Alzheimer's Disease, for which she received grants or contracts from Aegon Nederland and Alzheimer Nederland and royalties from Uitgeverij Prometheus. She received compensation for writings, presentations, or educational events on this topic from Zin Magazine, Psychologie Magazine, Libelle, NRC Media, Provincie Drenthe, Radboud UMC and Roche NL. She is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport. All payments are made to her LNCV is supported by a fellowship grant received from Alzheimer Nederland (WE.15-2019-05). She received a small fee for the development of an online course on shared decision making by EACH, the international organization for research in healthcare. Payments were made to her institution. FHB received grants, contracts, or consulting fees from Optina Diagnostics (Canada), Biogen and Roche. Payments were made to her institution. PS has received consultancy fees (paid to the institution) from AC Immune, Alkermes, Alnylam, Alzheon, Anavex, Axoltis, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Nordisk, PeopleBio, Renew LLC, Roche. He received payment or honoraria from Nutricia. He is PI of studies with AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, and Vivoryon. He is a part-time employee of Life Sciences Partners Amsterdam. He serves on the board of Brain Research Center and New Amsterdam Pharma. He participated on a Data Safety Monitoring Board or Advisory Board at Genentech. He is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport (paid to the institution). ALB received grants or contracts (paid to her institution) from Horizon2020 INKplant: "Ink-based hybrid multi-material fabrication of next generation implants" (2021-2025); COGEM (RIVM Committee on Genetic Modification) Grant: "The role and meaning of the concept 'naturalness' in scientific, legal and societal context" (2019-2021); Netherlands Organisation for Scientific Research (NWO) Crossover Grant: "INTENSE: Innovative Neurotechnology for Society" (2020-2025); Netherlands Organisation for Scientific Research (NWO): "RAIDIO: Responsible Artificial Intelligence for Clinical Decision-Making" (2020-2025); EU H2020 grant "EXPANSE: exposome empowered tools for healthy living in urban settings" (2020-2024); National Science Agenda (NWA): SYMPHONY: Orchestrating personalised treatment in patients with a bleeding disorder (2019-2023); Horizon2020 grant "iPSpine: induced pluripotent stem cell based therapy for spinal regeneration" (2019-2024). She is member of Dutch Senate (payment to her), Board of ZonMw (payment to her institution), Supervisory Board Amsterdam UMC (payment to her) International Society for Stem Cell Research Ethics Committee (no payment) and IQVIA's Ethics Advisory Panel (payment to her institution). Research programs of WMvdF have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. She holds the Pasman chair. She is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. She participated in an advisory board of Biogen MA Inc. She is associate editor at Brain. All funding is paid to her institution.
Funding Statement
Research of Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. JvdS is appointed at ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. PS is recipient of JPND-funded EURO-FINGERS (ZonMW-Memorabel #733051102).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A, as this is a systematic review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.